- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05363774
A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Doses of NNC0519-0130 in Healthy Participants and Multiple Subcutaneous and Oral Doses of NNC0519-0130 in Participants With Overweight or Obesity and Participants With Type 2 Diabetes
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Novo Nordisk
- Phone Number: (+1) 866-867-7178
- Email: clinicaltrials@novonordisk.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Single ascending dose (SAD) part:
- Male aged 18-55 years (both inclusive) at screening
- Body mass index between 18.5 kilogram per meter square (kg/m^2) and 27.0 kg/m^2 (both inclusive) at screening
- Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator
- Multiple ascending dose (MAD) part (MAD QD and MAD QW):
- Male aged 18-55 years (both inclusive) at screening
- Body mass index between 25.0 kg/m^2 and 39.9 kg/m^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator
- Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator
- Type 2 diabetes (T2D) part:
- Female of non-childbearing potential or male aged 18-64 years (both inclusive) at screening
- Body mass index between 25.0 kg/m^2 and 39.9 kg/m^2 (both inclusive) at screening
- Diagnosed with type 2 diabetes mellitus greater than or equal to (≥) 180 days before screening
- Treatment naive to antidiabetic drugs or on a stable daily dose(s) of metformin therapy (any metformin formulation any dose) greater than or equal to (>=) 60 days before screening
- Insulin naive. However, short-term insulin treatment for a maximum of 14 days before screening is allowed, as is prior insulin treatment for gestational diabetes
- HbA1c in the range of 6.5% (inclusive) and 9.5% (inclusive)
Exclusion Criteria:
- Single ascending dose (SAD) part:
- Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
- Glycosylated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 % (48 millimoles per mole (mmol/mol)) at screening
- Use of prescription medicinal products or non-prescription drugs, except routine vitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid, and domperidon, or topical medication not reaching systemic circulation, within 14 days before screening
- Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
- Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions
- HbA1c greater than or equal to (≥) 6.5 % (48 mmol/mol) at screening
- Use of prescription medicinal products or non-prescription drugs, except routine vitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid, and domperidon, or topical medication not reaching systemic circulation, within 14 days before screening
- Multiple ascending dose (MAD) part (MAD QD and MAD QW):
- Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
- Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions
- HbA1c greater than or equal to (≥) 6.5 % (48 mmol/mol) at screening
- Use of prescription medicinal products or non-prescription drugs, except routine vitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid, and domperidon, or topical medication not reaching systemic circulation, within 14 days before screening
- Type 2 diabetes (T2D) part:
- Any disorder, except for conditions associated with T2D, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
- Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with diabetes mellitus)
- Current treatment with systemically effective corticosteroids, monoamine oxidase (MAO) inhibitors, systemic non-selective beta-blockers, growth hormone, non-routine vitamins or herbal products
- Current treatment with selected oral medication with a narrow therapeutic window, such as warfarin, digoxin, tricyclic antidepressants, lithium, aminophylline, theophylline and anticonvulsants
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single ascending dose (SAD) part
Participants will receive up to six dose levels of subcutaneous NNC0519-0130 or matching placebo in a sequential manner with the dose increasing between cohorts.
|
SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts. MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels. SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts. MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive Placebo up to 6 dose levels. |
Experimental: Multiple ascending dose (MAD) QD part
MAD QD part comprises two cohorts in participants with overweight or obesity and a cohort in participants with type 2 diabetes (T2D).
The participants in first cohort will receive NNC0519-0130 or matching placebo subcutaneously up to 5 dose levels, and the participants in the second MAD QD cohort will receive NNC0519-0130 or matching placebo orally up to 5 dose levels.
|
SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts. MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels. SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts. MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive Placebo up to 6 dose levels. |
Experimental: Type 2 diabetes (T2D) part
Participants will receive NNC0519-0130 or matching placebo up to 2 dose levels with dose escalation within the cohort.
|
SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts. MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels. SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts. MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive Placebo up to 6 dose levels. |
Experimental: MAD QW part
MAD QW part comprises two cohorts in participants with overweight or obesity and who are otherwise generally healthy.
The participants in first cohort will receive NNC0519-0130 and 2nd cohort will receive matching placebo subcutaneously up to 6 dose levels.
|
SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts. MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels. SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts. MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels. T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort. MAD QW part: Participants will receive Placebo up to 6 dose levels. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of treatment emergent adverse events (TEAE) in single ascending dose (SAD) part
Time Frame: From time of dosing (day 1) until completion of the follow-up visit (assessed up to 22 days)
|
Measured as Number of events
|
From time of dosing (day 1) until completion of the follow-up visit (assessed up to 22 days)
|
Number of treatment emergent adverse events (TEAE) in the Multiple ascending dose with daily dosing (MAD QD) subcutaneous cohort
Time Frame: From time of dosing (day 1) until completion of the follow-up visit (assessed up to 133 days)
|
Measured as Number of events
|
From time of dosing (day 1) until completion of the follow-up visit (assessed up to 133 days)
|
Number of treatment emergent adverse events (TEAE) in MAD QW s.c. cohort
Time Frame: From time of first dosing (day 1) until completion of the follow-up visit (assessed up to 133 days)
|
Measured as Number of events
|
From time of first dosing (day 1) until completion of the follow-up visit (assessed up to 133 days)
|
Number of treatment emergent adverse events (TEAE) in T2D QW cohort
Time Frame: From time of dosing (day 1) until completion of the follow-up visit (assessed up to 133 days)
|
Measured as number of events
|
From time of dosing (day 1) until completion of the follow-up visit (assessed up to 133 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC0-∞,NNC0519-0130,SD: Area under the NNC0519-0130 plasma concentration-time curve from time 0 (time of dosing) to infinity after a single dose
Time Frame: From pre-dose (day 1) until completion of the follow-up visit (assessed up to 22 days)
|
Measured in h*nmol/L
|
From pre-dose (day 1) until completion of the follow-up visit (assessed up to 22 days)
|
Cmax,NNC0519-0130,SD: Maximum plasma concentration of NNC0519-0130 after a single dose
Time Frame: From pre-dose (day 1) until completion of the follow-up visit (assessed up to 22 days)
|
Measure in nmol/L
|
From pre-dose (day 1) until completion of the follow-up visit (assessed up to 22 days)
|
Number of treatment emergent adverse events (TEAE) in the MAD QD oral cohort
Time Frame: From time of dosing (day 1) until completion of the follow-up visit (assessed up to 112 days)
|
Measured as Number of events
|
From time of dosing (day 1) until completion of the follow-up visit (assessed up to 112 days)
|
AUC0-24h,NNC0519-0130,SS: Area under the NNC0519-0130 plasma concentration-time curve after the last dose in each treatment period in MAD QD part
Time Frame: From pre-dose (last dose in each treatment period) until 24 hours post-dose
|
Measured in h*nmol/L
|
From pre-dose (last dose in each treatment period) until 24 hours post-dose
|
Cmax,NNC0519-0130,SS: Maximum plasma concentration of NNC0519-0130 after the last dose in each treatment period in MAD QD part
Time Frame: From pre-dose (last dose in each treatment period) until 24 hours postdose
|
Measured in nmol/L
|
From pre-dose (last dose in each treatment period) until 24 hours postdose
|
AUC0-168h,NNC0519-0130,MD: Area under the NNC0519-0130 plasma concentration-time curve after the last dose in T2D QW cohort
Time Frame: From pre-dose (last dose) until 168 hours post-dose
|
Measured in h*nmol/L
|
From pre-dose (last dose) until 168 hours post-dose
|
Cmax,NNC0519-0130,MD: Maximum plasma concentration of NNC0519-0130 after the last dose in T2D QW cohort
Time Frame: From pre-dose (last dose) until 168 hours post-dose
|
Measured in nmol/L
|
From pre-dose (last dose) until 168 hours post-dose
|
AUC0-168h,NNC0519-0130,SS: Area under the NNC0519-0130 plasma concentration-time curve after the last dose in each treatment period in the MAD QW s.c. cohort
Time Frame: From pre-dose (last dose in each treatment period) until 168 hours post-dose
|
measured in h*nmol/L
|
From pre-dose (last dose in each treatment period) until 168 hours post-dose
|
Cmax,NNC0519-0130,SS: Maximum plasma concentration of NNC0519-0130 after the last dose in each treatment period in the MAD QW s.c. cohort
Time Frame: From pre-dose (last dose in each treatment period) until 168 hours post-dose
|
Measured in nmol/L
|
From pre-dose (last dose in each treatment period) until 168 hours post-dose
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Transparency dept. 2834, Novo Nordisk A/S
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN9541-4842
- 2021-004856-41 (EudraCT Number)
- U1111-1267-4254 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers (Diabetes Mellitus, Type 2)
-
Novo Nordisk A/SCompletedHealthy Volunteers Diabetes Mellitus, Type 2 | Healthy Volunteers Overweight | Healthy Volunteers ObesityNetherlands
-
Novo Nordisk A/SCompletedHealthy Volunteers Diabetes Mellitus, Type 2 | Healthy Volunteers Overweight | Healthy Volunteers ObesityNetherlands
-
Turku University HospitalUniversity of Turku; University of Helsinki; Academy of Finland; European Foundation... and other collaboratorsUnknownType 2 Diabetes Mellitus | Healthy VolunteersFinland
-
AstraZenecaParexelCompletedHealthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)Germany
-
Novo Nordisk A/SCompletedHealthy Volunteers (Diabetes Mellitus, Type 2)United Kingdom
-
University Hospital, MontpellierCompletedInsulin Resistance | Healthy Volunteers | Type 2 Diabetes (T2D)France
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | Healthy VolunteersChina
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | Healthy VolunteersGermany
-
Eli Lilly and CompanyCompleted
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | Healthy VolunteersGermany
Clinical Trials on NNC0519-0130
-
Novo Nordisk A/SNot yet recruiting
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Japan
-
Novo Nordisk A/SRecruitingDiabetes Mellitus, Type 2United States, Korea, Republic of, India, Australia, Canada, Japan, South Africa
-
Novo Nordisk A/SRecruitingObesityUnited States, Australia, Japan
-
Gilead SciencesTerminatedMetastatic Colorectal Cancer | Rectal Cancer | Colon CancerUnited States